Investors turn on CSL, delivering first strike on pay after poor year

view original post

CSL, the country’s largest pharmaceuticals group, has been forced to defend how much it is paying executives after investors delivered a so-called first strike against the remuneration plans following a challenging year.

Chairman Brian McNamee said CSL was in a unique position as one of few major biotech companies listed on the ASX. This meant it needed to compete with bigger rivals in the United States for talent.

Loading…